Scarica l'app Stockscreener
21.47
3.57%
0.74
Dopo l'orario di chiusura:
21.77
0.30
+1.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$20.73
Aprire:
$21
Volume 24 ore:
6.49M
Relative Volume:
2.53
Capitalizzazione di mercato:
$2.71B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-10.58
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-23.78%
1M Prestazione:
-5.13%
6M Prestazione:
+11.76%
1 anno Prestazione:
-21.24%
Intervallo 1D:
$19.25
$21.80
Intervallo di 1 settimana:
$19.25
$30.48
Portata 52W:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
21.47 | 2.62B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Is Apellis Pharmaceuticals Inc. stock attractive for income investorsRate Hike & Low Risk Entry Point Tips - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performanceQuarterly Profit Review & Daily Growth Stock Investment Tips - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery2025 Risk Factors & Expert Approved Momentum Ideas - newser.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockFed Meeting & Reliable Price Breakout Signals - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic value2025 Price Targets & High Return Stock Watch Alerts - newser.com
Will Apellis Pharmaceuticals Inc. (1JK) stock rise with strong economy2025 Institutional Moves & Safe Swing Trade Setup Alerts - newser.com
Apellis Pharmaceuticals Hits Day Low of $20.66 Amid Price Pressure - Markets Mojo
Brighton Jones LLC Buys Shares of 16,539 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc. recovery potential after sell off2025 Market WrapUp & Verified Momentum Stock Watchlist - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekWeekly Trend Recap & Smart Money Movement Tracker - newser.com
Why retail investors favor Apellis Pharmaceuticals Inc. stockJuly 2025 Closing Moves & Weekly Setup with ROI Potential - newser.com
Citigroup Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $45.00 at TD Cowen - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $45.00 by Analysts at HC Wainwright - MarketBeat
Robert W. Baird Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2025 Earnings Call Transcript - Insider Monkey
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.July 2025 Movers & Weekly High Return Opportunities - newser.com
Jennison Associates LLC Raises Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Y Intercept Hong Kong Ltd Has $2.84 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Will Apellis Pharmaceuticals Inc. stock maintain dividend yieldShort Setup & Smart Swing Trading Alerts - newser.com
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by AlphaQuest LLC - MarketBeat
How Apellis Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedPrice Action & Fast Gaining Stock Reports - newser.com
APLS: Citigroup Lowers Price Target Amidst Maintained Buy Rating - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownTime to Sell? - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastDividend Cut Warnings & Free Wealth Planning Blueprints - earlytimes.in
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates - sharewise.com
APLS Analyst Rating Update: TD Cowen Adjusts Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Beats Estimates By $0.64 EPS - MarketBeat
Apellis Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:APLS) 2025-10-31 - Seeking Alpha
Apellis Pharmaceuticals (APLS): Forecast 13% Annual Revenue Growth, Shares Trade at Deep Discount Heading Into Earnings - Yahoo Finance
APLS Stock: Baird Raises Price Target to $52, Maintains Outperfo - GuruFocus
APLS: HC Wainwright & Co. Lowers Price Target, Maintains 'Buy' Rating | APLS Stock News - GuruFocus
What valuation ratios show for Apellis Pharmaceuticals Inc. (1JK) stockTrade Risk Assessment & Low Volatility Stock Recommendations - newser.com
How moving averages guide Apellis Pharmaceuticals Inc. tradingMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings - TipRanks
Can Apellis Pharmaceuticals Inc. stock sustain market leadership2025 Pullback Review & Free Growth Oriented Trading Recommendations - newser.com
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
What high frequency data says about Apellis Pharmaceuticals Inc.2025 Market Sentiment & Free Community Consensus Stock Picks - newser.com
Apellis Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Apellis down as Goldman Sachs cuts to sell on risks to outlook - MSN
Apellis Pharma earnings beat by $0.12, revenue topped estimates - Investing.com Canada
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash - ts2.tech
Apellis (APLS) Shares Decline by Nearly 25% - GuruFocus
CapEx per share of Apellis Pharmaceuticals, Inc. – MUN:1JK - TradingView
Earnings call transcript: Apellis Pharmaceuticals Q3 2025 earnings beat expectations but stock tumbles - Investing.com Nigeria
Apellis (APLS) Shares Drop Sharply by Over 19% - GuruFocus
Apellis Gets A Rare Edge With Big Sobi Payout And Strong Drug Sales - Finimize
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):